Michael Joseph Rybak PharmD, MPH, PhD, FCCP, FIDSA, FIDP

Michael J. Rybak, Pharm.D., M.P.H., PH.D., FCCP, FIDSA, FIDP is Professor of Pharmacy, Department of Pharmacy Practice, adjunct Professor of Pharmaceutical Sciences, and Director, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University. He is also an adjunct Professor of Medicine, Division of Infectious Diseases, School of Medicine, Wayne State University, and adjunct Professor of Pharmacy-Clinical, College of Pharmacy, University of Michigan.

Dr. Rybak’s research focus is antimicrobial pharmacokinetics and pharmacodynamics (PK/PD) and the assessment of infectious disease's health outcomes including their relationship to bacterial resistance. His most recent work is focused on the use of combination therapy to prevent resistance. Dr. Rybak is funded by the National Institute for Allergy and Infectious Diseases (NIAID) and via several investigator-initiated grants from Pharmaceutical Industry. He has published more than 390 manuscripts and authored 20 book chapters on antimicrobial PK/PD, resistance, and antimicrobial stewardship.

He is the editor-in-chief of the journal Infectious Diseases and Therapy and a scientific editor for Infectious Diseases for Pharmacotherapy, editorial board member for Critical Reviews in Microbiology. He is a reviewer for several leading publications including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy, Open Forum Infectious Diseases, and Lancet ID. Dr. Rybak has served on the guideline committees for MRSA infections, Infective Endocarditis and is the Chair of the Vancomycin Consensus Guidelines Committee.